Two interesting posts by PP on Prurisol. PlentyParanoid

New Post Public Reply Private Reply Replies (0) Message Board
sox0407
455
Two interesting posts by PP on Prurisol.

PlentyParanoid Monday, 04/16/18 12:08:12 PM
Re: loanranger post# 224383
Post # 224477 of 224506

Oh darn, I was afraid that my post might misfire. Loanranger, you are absolutely right about my post being obscure. I try to clarify.

How do PASI and sPGA scores relate to each other:
PASI50 score is roughly equivalent to sPGA score reduction by 1 point (often called sPGA shift 1)
PASI75 score is about equal to sPGA score 0/1 with at least 2 point reduction from baseline sPGA index
PASI90 does not have equivalent in sPGA world
PASI100 is about equal to sPGA 0 with at least 2 point reduction

In practise and only for subjects with moderate to (very) severe psoriasis
PASI75 score is about 1.15 +- 0.25 (st.dev) times sPGA0/1 score based on a sample of 200 value pairs. About 75 % of ratios were above 1.0.
PASI100 score is about 0.9 +- 0.20 (st.dev) times sPGA0 score based on a sample of 50 value pairs. About 75 % of ratios were below 1.0.
The drop in PASI/sPGA ratio reflects relative weakening of sPGA score definition from 0/1 to 0. Strict sPGA equivalent to PASI100 would be sPGA score 0 with at least 3 point reduction in sPGA score, not by 2 points as it is now.

What I was trying to demonstrate was
1. Quite a number of kill/continue decisions on psoriasis drugs have been based on trials with similar population sizes as in prurisol p2a trial.
2. All kill decisions in my sample were based on weaker efficacy numbers than those for prurisol.
3. Even the two go ahead decisions in my sample were based on weaker efficacy numbers than those for prurisol.
4. The one drug in my sample, CF101, that failed in p3 should not have been there in the first place. It got to p3 only because of an astoundingly flawed phase 2 data analysis.
5. If prurisol were a big pharma drug it probably would be in late p2 or p3 trial right now, which, strangely, is the case right now. What a flabbergasting coincidence.

Specifically about Otezla: decision to proceed with Otezla was based on trials with 20 mg BID dose and PASI75 scores 24.4 and 30 %. Afterwards, in dose ranging trials optimal dose was deemed to be 30 mg BID. For 30 mg dose Otezla trials have recorded PASI75 values in the range 28.7 to 40.9 % and sPGA 0/1 values in the range 20.4 to 33 %. About the same as for prurisol 200 mg in p2a (for Otezla PASI75 to sPGA 0/1 ratio is anywhere from 1.11 to 1.53, depending on a trial). Highest PASI100 or sPGA0 reported for Otezla is 3.4 %.

In conclusion
A. It looks like results from small psoriasis trials do indicate significant efficacy trends.
B. Irony is obviously lost in salad eating hop-alongs.
C. I am not saying that prurisol is a sure winner. Neither am I saying that PASI75 score for prurisol 300 mg dose will be above 50 %. I doubt that. What I am saying is that, so far, indication are pointing more into winning direction than into losing. What convinced me of this is prurisol's 10.5 % score for sPGA 0. sPGA0 scores above 2 % for placebo have NOT been reported as far as I know and, in general, sPGA0 above 10 % is reserved for biologicals.

Opposition case: the points TIAB should be making are:
Fine, prurisol shows some indications of efficacy. But:
1. We do not have any evidence that this efficacy will scale upward with dose. Both bell shaped (CF101) and quickly saturating efficacy/ dose curves have been reported.
2. There is no guarantee that the efficacy level shown in p2a will survive in larger trials. The size of p2a trial is too small to infer that; granularity in efficacy is of the order of 5 % per subject. Therefore, efficacy in larger trial could as well be 20 or 25 % percent measured by sPGA 0/1 ie. below or at the clear stop/go threshold. Prurisol is probably dead if sPGA 0/1 for prurisol in p2b turns out to be about 20 %.

We have a case of different opinions based on incomplete set of facts. I have as much evidence (well, probably bit more) to say that prurisol will succeed than TIAB has to say it will not. TIAB's problem is that sPGA 0 score for prurisol.

Sorry about the length of the post. My bad habit. I even lecture to audience of 2 (me and myself).

PlentyParanoid Sunday, 04/15/18 05:17:53 PM
Re: TheBunny post# 224372
Post # 224373 of 224508

Incomplete history of psoriasis treatment failures in phase 2

I took it to myself to provide some scientific support for TIAB’s position that prurisol 2a trial results don’t have any scientific or predictive value and hence are a gross insult to stuff that is mere useless.

Below are psoriasis p2 trials for some compounds that got terminated at phase 2 or went to die in phase 3.

Apo805K1 p2 with 12 subjects, scored PASI75 of 16.7 %. Promptly forgotten.
Lipitor p2 with 11 subjects, scored PASI 50 of 27.3 %. Instantly killed for psoriasis.
CF101 p2 with 17 subjects scored PASI50 of 35.3%, PASI 75 of 5.9%, sPGA 0/1 of 23.5 %. This one went to die in P3 with PASI75 score at 8.5% and equaling placebo. Turns out that the Co. had forgotten from sPGA 0/1 definition the part saying ‘and improvement of at least 2 sPGA points'. The real sPGA 0/1 in p2 was 5.9 %.
Doxercalciferol p2 with 25 subjects scored PASI50 of 20 %. Buried.
Navarixin p2 with 21 subjects scored sPGA 1 point shift of 38.1% (about the same or slightly worse in terms of PASI50). Swiftly nixed.
PF-04965842 p2 with 14 subjects scored PASI75 of 14.3 %. Terminated with prejudice.
SRT2104 p2 with 12 subjects scored sPGA 0/1 of 16.7 %. Mercifully removed from life support.
Talarozole p2 with 45 subjects scored PASI75 of 15.6 %. Dropped like dead pigeon.

For comparison, a succesful transition from p2 to market:
Apremilast (Otezla) p2 with 30 subjects and 20 mg dose scored PASI50 of 46.7 %, PASI75 of 30.0 and went thru successful P3 to generate over 1 B$ in yearly sales.

So, how does those numbers for prurisol look in this company
Prurisol p2 with 19 (sPGA=3) subjects and 200 mg dose scored sPGA0/1 of 31.6 % and sPGA 0 ( about equal to PASI 100) of 10.5 %. Even ignoramus can see that these number don’t show any sort positive trend. And if not an ignoramus then surely an educated man. And if not an educated man then unquestionably a pre-med student who paid for his chemistry and biology grades. And if not him then, well <que in the music>
Somebody (somebody)
ooh somebody (somebody)
Can anybody find me somebody ...

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Dont-give-up.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 66

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 58

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 73

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 74

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 81

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 80

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 187

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 135

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 138

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading

Top 5 Most Recently Viewed Articles

Nabors Industries Expands Reach with Parker Wellbore Buyout

Updated Category News Views 205

Nabors Industries Completes Acquisition of Parker Wellbore Nabors Industries Ltd. (NYSE: NBR) has officially concluded its acquisition of Parker Wellbore, a strategic move that strengthens Nabors' leadership in drilling and associated value-added services. This acquisition not only cements Nabors' robust market position but also enhances its service capabilities across...

Continue Reading
Utz, Integer, Arcosa, Dominion: Fair Deals for Shareholders?

Updated Category News Views 18

Investor Concerns Over Recent M&A Deals Today, you can't shake a stick without hitting some M&A news and, frankly, these deals with Utz, Integer, Arcosa, and Dominion have got investors squirming in their seats. With insiders possibly raking in the dough, shareholders are left wondering if they’re just getting table scraps. And you know what makes folks justifiably...

Continue Reading
Revolutionizing Business Growth with QuickBooks AI Tools

Updated Category News Views 151

Revolutionizing Business Growth with QuickBooks AI Tools Software Experts recently spotlighted QuickBooks for its innovative approach in transforming business financial forecasting and planning. The introduction of AI-driven agents in QuickBooks signifies a major transition towards more connected and automated financial management, streamlining processes while enhancing...

Continue Reading
CMB Certification: A New Era for Sustainable Wellness Brands

Updated Category News Views 234

CMB Certification: Pioneering a Path for Wellness Brands Crunchy Mama Box (CMB) has recently unveiled its CMB Certification Program, an initiative that aims to validate wellness brands dedicated to sustainability, ethical practices, and social contributions. This certification serves as a valuable tool for consumers, empowering them to make well-informed decisions while...

Continue Reading
Prevounce Health Integrates AI for Enhanced Patient Care Solutions

Updated Category News Views 303

Prevounce Health Enhances Remote Care with Innovative AI Insights Prevounce Health has recently unveiled an exciting feature that integrates artificial intelligence into its remote care management offerings. This initiative aims to provide AI-generated summaries and personalized recommendations for patients enrolled in remote care management programs, transforming the...

Continue Reading